What is Biosense?
Biosense operates at the intersection of digital health and metabolic science, providing a clinically validated breath ketone monitor that delivers real-time biofeedback. By utilizing deep lung air sampling, the device offers a sophisticated, non-invasive alternative to traditional blood-based ketone testing, effectively removing the friction associated with finger-prick diagnostics. The company serves a growing demographic of health-conscious individuals and metabolic experts who prioritize precision in tracking fat-burning processes and personalized wellness goals. Through its focus on user-centric design and scientific rigor, Biosense has established a unique market position as a leader in accessible metabolic monitoring, catering to the increasing demand for data-driven health optimization tools.
How much funding has Biosense raised?
Biosense has raised a total of $2.2M across 1 funding round:
Angel/Seed
$2.2M
Angel/Seed (2020): $2.2M with participation from iSelect Funds
Key Investors in Biosense
iSelect Funds
A venture capital firm specializing in early-stage investments within the life sciences and health-tech sectors, focusing on companies that drive innovation in human health and wellness.
What's next for Biosense?
With this latest infusion of capital, Biosense is poised to transition from its initial development phase into a period of aggressive market expansion. The strategic roadmap likely includes enhancing the device's software ecosystem to provide deeper analytical insights, alongside scaling manufacturing capabilities to meet rising consumer demand. By leveraging its current momentum, the company aims to solidify its presence in the wellness technology landscape, potentially exploring partnerships with metabolic health clinics and digital fitness platforms. As the firm continues to refine its biofeedback algorithms, it remains focused on delivering actionable health intelligence that empowers users to achieve sustainable metabolic health outcomes.
See full Biosense company page
